Brain Cancer Clinical Trials in Michigan

Showing 21-40 of 69 trials

Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures

NCT07225101

This research is studying a device already approved by the Food and Drug Administration (FDA) to treat wound closures. Researchers are studying a large group of people to continue to learn information about the safety of the STRATAFIX suture and how people's bodies react to using it over a long period of time. This research will provide additional information about using STRATAFIX sutures to close surgical wounds.

Wound ClosureBrain Tumor AdultSpine+3 more

University of Michigan160 participantsStarted Nov 2025

Lansing, Michigan, United States

COMPLETEDPHASE348 miles

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

NCT00716976

RATIONALE: Sodium thiosulfate may reduce or prevent hearing loss in young patients receiving cisplatin for cancer. It is not yet known whether sodium thiosulfate is more effective than no additional treatment in preventing hearing loss. PURPOSE: This randomized phase III trial is studying sodium thiosulfate to see how well it works in preventing hearing loss in young patients receiving cisplatin for newly diagnosed germ cell tumor, hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, or other malignancy.

Brain TumorCentral Nervous System TumorChildhood Germ Cell Tumor+6 more

Children's Oncology Group131 participantsStarted Jun 2008

Birmingham, Alabama, United States • Little Rock, Arkansas, United States • Los Angeles, California, United States +73 more locations

Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Brain Cancer Trials in Other Cities

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

9-ING-41 in Pediatric Patients With Refractory Malignancies.

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Expanded Access Protocol Using 131I-MIBG

Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Glioma Supra Marginal Incision Trial

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas

Other Conditions in Michigan